Concert Pharmaceuticals, Inc. | TalkMarkets

Latest Posts

5 Stocks To Bet On New Analyst Coverage

Article By: Zacks Investment Research

Monday, August 21, 2017 12:32 PM EDT

As analysts are one of the most important information intermediaries in capital markets, initiation of coverage by them creates value for companies.

In this article: CMCO, ACET, CNCE, APPF, FWONA

Read

After Valeant, Here Are 5 Drug Stocks Bill Ackman Should Buy Instead

Article By: Arpita Dutt

Wednesday, March 15, 2017 12:57 PM EDT

Here is a look at 5 drug stocks that could find a place in Ackman’s investment plans.

In this article: NEOS, CNCE, LOXO, NDRM, BCRX Also: VRX

Read

Biotech Stock Roundup: Trump Tweet Hits Biotech Stocks, Concert Gains On Vertex Deal

Article By: Arpita Dutt

Wednesday, March 8, 2017 9:08 AM EDT

A tweet kept the biotech industry on edge with President Donald Trump declaring that he is “working on a new system where there will be competition in the Drug Industry” and “pricing for the American people will come way down”.

In this article: CNCE, IONS, JUNO, CELG Also: VRTX, GILD, BIIB

Read

Monday’s Biotech Insights: Concert Pharmaceuticals Inc (CNCE), TG Therapeutics Inc (TGTX)

Article By: Smarter Analyst

Monday, March 6, 2017 3:58 PM EDT

CNCE shares skyrocketed today following the news that Vertex Pharmaceuticals (NASDAQ:VRTX) will acquire Concert’s deuterated Kalydeco variant, CTP-656, for $160 million upfront with up to $90 million in milestones.

In this article: CNCE, VRTX

Read